Phase II Study of Recombinant Anti-tumor and Anti-Virus Protein for Injection Plus Capecitabine in Treating Patients With Metastatic Colorectal Cancer After Failure of Standard Treatment

Trial Profile

Phase II Study of Recombinant Anti-tumor and Anti-Virus Protein for Injection Plus Capecitabine in Treating Patients With Metastatic Colorectal Cancer After Failure of Standard Treatment

Recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Aug 2017

At a glance

  • Drugs Capecitabine (Primary) ; Novaferon (Primary)
  • Indications Adenocarcinoma; Colorectal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 Jan 2016 Planned End Date changed from 1 Dec 2015 to 1 Dec 2016 as per ClinicalTrials.gov record.
    • 04 Jan 2016 Planned primary completion date changed from 1 Nov 2015 to 1 Nov 2016 as per ClinicalTrials.gov record.
    • 25 Aug 2015 Planned End Date changed from 1 Apr 2015 to 1 Dec 2015 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top